Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT04711551
Recruiting Observational

Clinical and Biomolecular Assessment for the Monitoring of Patients Undergoing Regenerative Medicine Treatments with Orthobiologics

NCT04711551 · tracked via the Priya Life Science Italy tracker
Sponsor
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Phase
Observational
Started
2018-05-30
Last updated
2025-02-17

Condition(s) studied

Musculoskeletal System Disease

Investigational drug(s) / intervention(s)

PRP and related devices to abtain platelet concentrate from whole blood, medullary and adipose tissue and related devices

PRP and related devices to abtain platelet concentrate from whole blood, medullary and adipose tissue and related devices: PRP and related devices to abtain platelet concentrate from whole blood, medullary and adipose tissue and related devices

Study summary

the aim is to improve the evaluation of the outcomes of regenerative medicine treatments performed in the regenerative medicine centers involved in the study.

patients who undergo regenerative medicine treatments present acute and chronic pathologies of the musculoskeletal system, of the stomatological system and of the integuments.

Objective pre, peri and post treatment evaluations are collected. A dedicated software collects the PROMs compiled by the patients, the objective clinical data and the biomolecular evaluations.

Eligibility

Sex
ALL
Min age
6 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * patients who received indication for regerative medicine treatment for one of the following pathologies: Knee or hip or ankle osteoarthritis, patellar or Achilles tendon pain, shouder or elbow pain; * males and females; * age \>= 6 years. Exclusion Criteria: * age \< 6 years * patients not compliant with post-treatment monitoring procedures * pregnancy

Primary outcome measure(s)

  • Change in Visual Analog Scale — Change between baseline and 12 months
    Pain will be measured with Visual Analog Scale (0-10, where 0 rapresents absence of pain and 10 the maximum pain possible) before and after treatment.

Trial sites (2)

FacilityCityRegionStatus
Istituto Clinico San Siro (satellite center) Milan Italia Recruiting
IRCCS Ospedale Galeazzi-Sant'Ambrogio (coordinator) Milan Italy Recruiting

More I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio trials in Italy

Metabolic Profile of Bone in Professional Athletes Recruiting
Extracellular Vesicles in Fibrin Gel for Cartilage Repair Recruiting
ACL Reconstruction in Patients Aged 50 Years and Older Active, not recruiting
Evaluation of Limb Function and Perception in Rehabilitation After Traumatic Wrist Fracture Surgery Starting soon
The Influence of Perioperative Strategies on the Extent of in Orthopaedic Prosthetic Surgery Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04711551 on ClinicalTrials.gov ↗ ← All trials in Italy